Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype

Bulletin from the Extraordinary General Meeting of Hansa Medical AB

Regulatory information
On October 29, 2018, Hansa Medical AB (NASDAQ Stockholm: HMED) held an extraordinary general meeting. The following resolution was passed at the general meeting.

Approval of the board’s proposal to authorize the board to resolve on new issues of ordinary shares

The general meeting resolved to authorize the board, for the period up to the next annual general meeting, to adopt decisions, whether on one or several occasions and whether with or without pre-emptive rights for the shareholders, to issue new common shares, provided that such issues, in aggregate, must not exceed ten percent of the total number of outstanding common shares in the Company as of the date of the extraordinary general meeting.

The purpose of the authorization is to increase the financial flexibility of the Company and the acting scope of the board of directors, as well as to potentially broaden the shareholder base.

The information was submitted for publication, through the agency of the contact person set out below, on October 29, 2018 at 11:00am CET.